(MENAFN- Baystreet.ca) Alexion Pharmaceuticals, Inc. (NYSE:ALXN) fell back in Friday trading, on revealing that ULTOMIRIS has received marketing authorization from the European Commission for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.
The Boston-based company reported Wednesday the OK from the E.C., claiming ULTOMIRIS® (ravulizumab) as the first and only long-acting C5 complement inhibitor administered every eight weeks, for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) with hemolysis with clinical symptoms indicative of high disease activity.
The treatment is also advised for adult patients who are clinically stable after having been treated with SOLIRIS® (eculizumab) for at least the past six months.
PNH is an ultra-rare and severe disease that, when left untreated, may cause a wide range of debilitating symptoms and complications, including thrombosis.
Thrombosis occurs when a blood clot presents inside a blood vessel and slows or blocks the flow of blood through the circulatory system. Serious cases of thrombosis can occur throughout the body and result in organ damage, stroke, heart attack, and potentially premature death
The U.S. Food and Drug Administration (FDA) approved ULTOMIRIS (ravulizumab-cwvz) for adults with PNH last December. The Japanese Ministry Of Health, Labour And Welfare (MHLW) approved ULTOMIRIS as a treatment for adults with PNH on June 18 of this year.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing therapies
Alexion shares fell 24 cents to $133.11, soon after Friday's open
MENAFN0507201902120000ID1098727212
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.